Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | MMP1 | P03956 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
| ▸ | MMP8 | P22894 | 1/20 | 0.51 |
| ▸ | MMP13 | P45452 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 2/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14810148 | 0.81 | CA1 (0.56) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL28298275 | 0.79 | GAA (0.59) | CA1MAPTRAB9APOLBGAA | |
| SCHEMBL25047 | 0.78 | NFKB1 (0.42) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL23846018 | 0.77 | NFKB1 (0.41) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL17308770 | 0.77 | FABP4 (0.49) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL29188855 | 0.77 | CA1 (0.64) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL28280979 | 0.76 | CA12 (0.42) | CA1CA2CA12CA14CA7 | |
| SCHEMBL7982641 | 0.76 | CA1 (0.40) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL9176627 | 0.75 | CA1 (0.62) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL497667 | 0.75 | NFKB1 (0.53) | CA1CA2MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275664-A1 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | PROGEN PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20080194697-A1 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | CELLGATE, INC. | 2008-08-14 | — | — | US | disclosed |
| US-7312244-B2 | Polyamine analog-amino acid conjugates useful as anticancer agents | CELLGATE, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7279502-B2 | Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases | CELLGATE, INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-20070161692-A1 | Conformationally restricted polyamine analogs as disease therapies | CELLGATE, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-7186825-B2 | Conformationally restricted polyamine analogs as disease therapies | CELLGATE, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1698629-A2 | Polyamines and their use in therapy | Cellgate, Inc. (US) | 2006-09-06 | — | — | EP | disclosed |
| US-7094808-B2 | Analogs of biologically active, naturally occurring polyamines, pharmaceutical compositions and methods of treatment | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2006-08-22 | — | — | US | disclosed |
| EP-1177197-B1 | POLYAMINES AND THEIR USE IN THERAPY | CELLGATE INC (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20050233943-A1 | Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases | CELLGATE, INC. | 2005-10-20 | — | — | US | disclosed |
| EP-1337504-A2 | NOVEL POLYAMINE ANALOG-AMINO ACID CONJUGATES USEFUL AS ANTICANCER AGENTS | Slil Biomedical Corporation (US) | 2003-08-27 | — | — | EP | disclosed |
| US-20030100615-A1 | Analogs of biologically active, naturally occurring polyamines, pharmaceutical compositions and methods of treatment | BERGERON RAYMOND J (US) | 2003-05-29 | — | — | US | disclosed |
| WO-2002091989-A2 | ANTIVIRAL THERAPIES USING POLYAMINE OR POLYAMINE ANALOG-AMINO ACID CONJUGATES | SLIL BIOMEDICAL CORPORATION (US) | 2002-11-21 | — | — | WO | disclosed |
| US-20020143068-A1 | Analogs of biologically active, naturally occurring polyamines, pharmaceutical compositions and methods of treatment | BERGERON RAYMOND J (US) | 2002-10-03 | — | — | US | disclosed |
| WO-2002038105-A2 | NOVEL POLYAMINE ANALOG-AMINO ACID CONJUGATES USEFUL AS ANTICANCER AGENTS | SLIL BIOMEDICAL CORPORATION (US) | 2002-05-16 | — | — | WO | disclosed |
| US-6342534-B1 | BRIDGING GROUPS MAINTAIN DISTANCE BETWEEN NITROGEN ATOMS BINDING VIA ELECTROSTATIC INTERACTION TO COUNTER-ANIONS; ANTITUMOR,ANTICARCINOGENIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2002-01-29 | — | — | US | disclosed |
| EP-1173223-A2 | CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | Slil Biomedical Corporation (US) | 2002-01-23 | — | — | EP | disclosed |
| US-6184232-B1 | AMINE ADDUCT WHICH COMPETETIVELY BINDS WITH TARGET CELL COUNTERION AND FUNCTIONS DIFFERENTLY COMPARED TO NATURAL INTRACELLULAR POLYAMINES; ANTICARCINOGENIC AGENTS | UNIVERSITY OF FLORIDA | 2001-02-06 | — | — | US | disclosed |
| WO-2000066175-A2 | CONJUGATES AS THERAPIES FOR CANCER AND PROSTATE DISEASES | SLIL BIOMEDICAL CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
| US-5886051-A | MODULATORS OF THE N-METHYLASPARTIC ACID RECEPTOR; AGONISTS AND ANTAGONISTS; ALZHEIMER'S DISEASE; COGNITION ACTIVATORS; ACYCLIC AND CYCLIC COMPOUNDS HAVING TWO OR MORE SECONDARY AMINES | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 1999-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100615-A1 | Analogs of biologically active, naturally occurring polyamines, pharmaceutical compositions and methods of treatment | SLC7A1, SRM, SLC1A5 | CA1 772/4885CA2 433/4885MMP1 2891/4885 |
| US-20070161692-A1 | Conformationally restricted polyamine analogs as disease therapies | SRM, PYCR1, PAICS | CA1 3306/4885CA2 4601/4885MMP1 3970/4885 |
| US-20080194697-A1 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | CTSB, KLK3, FOLH1 | CA1 1706/4885CA2 3451/4885MMP1 1849/4885 |
| US-20020143068-A1 | Analogs of biologically active, naturally occurring polyamines, pharmaceutical compositions and methods of treatment | SLC7A1, SRM, SLC1A5 | CA1 772/4885CA2 433/4885MMP1 2891/4885 |
| US-20050233943-A1 | Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases | CTSB, CTSL, CTSV | CA1 1486/4885CA2 3220/4885MMP1 1468/4885 |
| US-20090275664-A1 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES | CTSB, CTSL, CTSV | CA1 1486/4885CA2 3220/4885MMP1 1468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.